Skip to content

Author

M. Polito

We have 4 of 27 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance

Bone metastases are a major complication of advanced solid tumors and are associated with substantial morbidity and reduced survival. Imaging plays a central role in detection and monitoring, yet conventional modalities and qualitative risk scores remain limited by suboptimal specificity and inter-reader variability. A...

L. Sisca, M. Polito, Emy Sisca et al. · 0 citations
Review Open access Sep 2026

Chemotherapy backbone and outcomes of immune checkpoint inhibitor combinations across solid tumors: a pan-tumor network meta-analysis

Abstract Background Immune checkpoint inhibitors (ICIs) combined with chemotherapy represent a first-line standard across multiple solid tumors; however, the contribution of chemotherapy backbone to the efficacy of chemo-immunotherapy remains uncertain. Methods We conducted a systematic review and network meta-analysis...

L. Sisca, M. Polito, A. Cortellini et al. · 0 citations
Review Open access Sep 2026

Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials

Findings support the efficacy of adjuvant ICIs across multiple solid tumors, with consistent improvements in DFS/RFS and a significant pooled OS benefit, and exploratory meta-regression suggested that tumor type may contribute to between-study heterogeneity.

M. Polito, L. Sisca, D. Caruso et al. · 0 citations
Review Open access Aug 2026

Circulating Tumor DNA in Bladder Cancer: Current Clinical Evidence and Emerging Multi-Omics Perspectives—A Narrative Review

The current evidence on the clinical applications of circulating tumor DNA in muscle-invasive bladder cancer is summarized, including its role in prognosis, treatment selection, and surveillance, and future perspectives for integrating molecular monitoring into personalized cancer care are discussed.

M. Polito, L. Sisca, D. Caruso et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.